Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy
Abstract Background A 3-year single-centre, retrospective, comparative, non-randomized cohort study to describe the long-term outcomes of treatment-naïve, Caucasian and non-Caucasian eyes with polypoidal choroidal vasculopathy (PCV) after treatment with predominantly Bevacizumab monotherapy or in co...
Main Authors: | Aaron Yap, Nancy Wang, David Squirrell |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-07-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12886-022-02551-3 |
Similar Items
-
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
by: Sumit Randhir Singh, et al.
Published: (2019-01-01) -
Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
by: Zeynep Alkin, et al.
Published: (2016-12-01) -
Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy
by: Mümin Hocaoğlu, et al.
Published: (2016-01-01) -
Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy
by: Kapil G. Kapoor, et al.
Published: (2015-12-01) -
Polypoidal Choroidal Vasculopathy: An Update on Therapeutic Approaches
by: Raymond L.M. Wong, et al.
Published: (2013-01-01)